ScholarWorks@Korea University College of Medicine: Yoon, Won Sup

Detailed Information

Yoon, Won Sup (윤원섭)

Ansan Hospital (Department of Radiation Oncology, Ansan Hospital)

Research Area

Tel
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Radiotherapy:24||radiotherapy:16||Hepatocellular carcinoma:12||hepatocellular carcinoma:10||Breast cancer:10||Radiation therapy:8||Stereotactic body radiotherapy:8||radiation therapy:4||Brain metastasis:4||Adjuvant radiotherapy:4||metaanalysis:4||Uterine cervical cancer:3||sorafenib:3||lung cancer:3||Spectrophotometer:3||stereotactic body radiotherapy:3||feasibility:3||Overall survival:3||survival:3||Adjuvant chemoradiotherapy:3||rectal cancer:3||external beam radiotherapy:3||Metaanalysis:3||ultracentral tumor:3||Liver neoplasm:3||Adjuvant:2||IntensityModulated Radiation Therapy:2||Cholangiocarcinoma:2||Breast neoplasm:2||NSCLC:2||Portal vein thrombosis:2||external beam radiation therapy:2||External beam radiation therapy:2||Biological index:2||head and neck cancer:2||Preoperative chemoradiotherapy:2||toxicity:2||transarterial chemoembolization:2||BCLC C:2||Prognosis:2||Prognostic factor:2||intensitymodulated radiotherapy:2||방사선치료:2||liver neoplasm:2||Cancer:2||Survival:2||Lung cancer:2||Tomotherapy:2||Quality of life:2||Gel dosimeter:2||Optical CT scanner:2||Complications:2||Radiofrequency ablation:2||Radiological properties:2||Endometrial cancer:2||portal vein thrombosis:2||Utilization:2||Magnetic resonance imaging:2||Organs at risk:2||Rectal neoplasms:2||Wholebrain radiotherapy:2||Recurrence:2||PRESAGE (TM) gel dosimeter:2||breast cancer:2||Imageguided radiotherapy:2||Right atrium:2||central tumor:2||chemoradiotherapy:2||Inferior vena cava:2||Risk factors:2||Heart:1||Hepatic arterial infusion chemotherapy:1||Hepatic toxicity:1||Hepatocellular Carcinoma:1||High grade glioma:1||Highdoserate brachytherapy:1||Hypofraction:1||IMRT:1||Image registration:1||Imageguided radiation therapy:1||Immobilization:1||Initiative:1||Intensitymodulated radiation therapy:1||Intraluminal brachytherapy:1||Intraoperative radiation therapy:1||Korea:1||Lamina propria:1||Life expectancy:1||Local control:1||Locoregional Control:1||Lymphadenectomy:1||Lymphatic Metastasis:1||Lymphatic metastasis:1||MRI:1||MVCT:1||Major complication:1||Mammaplasty:1||Management:1||Maxillary sinus:1||Meningioma:1||Metachronous Neoplasm:1||Metaruleguided mining:1||NSCLC IIIC:1||Nasopharyngeal carcinoma:1||Neoplasm Metastasis:1||Network metaanalysis:1||New Paradigm for Radiotherapy Payment:1||Nomogram:1||Nonscattering gel:1||Nonsmall cell lung cancer:1||Nonsmallcell lung carcinoma:1||Normal tissue complication probability:1||Onboard imager:1||Optimal wavelength:1||Optimization:1||Organ movement:1||Paraaortic recurrence:1||Patient motion:1||Pattern of care study:1||Pelvic neoplasms:1||Physical activity:1||Pituitary adenoma:1||Policy:1||Polymer gel:1||Portal vein:1||Postoperative:1||Postoperative chemoradiotherapy:1||Postoperative radiotherapy:1||Proctitis:1||Prognostic factors:1||Prognostic model:1||Prostate cancer:1||Quality:1||Quality assurance:1||Quality factor:1||Radiation pneumonitis:1||Radiation protection:1||Radiochromic gel:1||Radiosurgery:1||Radiotherapy dosage:1||Rectal cancer:1||Recurrence patterns:1||Reirradiation:1||Respiration:1||Right decision:1||Risk factor:1||Robotic couch:1||Salvage treatment:1||Sarcoma:1||Scan image control:1||Scoring system:1||Secondary biliary tumor:1||Selective internal radiotherapy:1||Sequence:1||Setup error:1||Setup uncertainty:1||South Korea:1||Stage:1||Stereotactic Radiotherapy:1||Stereotactic ablative body radiotherapy:1||Stereotactic radiotherapy:1||Surgery:1||Survival rate:1||Survivorship:1||Toxicity:1||Toxicity prediction:1||Treatment outcome:1||Treatment planning decision support system:1||Triphala:1||Tubular carcinoma:1||Tumor molecular subtype:1||Tumor tracking:1||Uterine Carcinosarcoma:1||Uterine Cervical Neoplasm:1||Uterine cervical neoplasms:1||Vaginal Neoplasms:1||Virtual organ delineation (VOD):1||Whole brain radiotherapy:1||Zebrafish:1||bone metastases:1||bone metastasis:1||breast reconstruction:1||cancer:1||cancer survivor:1||circumferential extent:1||clinical trials:1||combined:1||combined modality therapy:1||concurrent:1||consistency:1||couch:1||delay time:1||dietary habit:1||fractionated stereotactic radiotherapy:1||gastric cancer:1||guidelines:1||hepatocellular:1||highdose:1||imageguided radiation therapy (IGRT):1||inferior vena cava:1||intensitymodulated radiation therapy:1||interfractional variation:1||interruption:1||liver cancer:1||lymph node:1||lymph node metastasis:1||lymph nodes:1||mastectomy:1||metastasis:1||mistletoe:1||nonsmall cell lung carcinoma:1||oligometastasis:1||onboard imagers:1||organ at risk:1||pathologic tumor regression grade:1||pelvic irradiation:1||perioperative:1||planning target volume:1||portal vein tumor thrombus:1||portal vein tumour thrombosis:1||predictive modelling:1||preoperative chemoradiotherapy:1||preoperative concurrent chemoradiotherapy:1||preoperative radiotherapy:1||prognostic factors:1||prostate cancer:1||pulmonary metastasis:1||quality of life:1||questionnaire:1||radiation treatment planning (RTP) system:1||radiation treatment planning decision support program (PDSS):1||radiationinduced liver disease:1||radiochemotherapy:1||radiomics:1||radioprotectant:1||radiotherapy dosage:1||reconstruction:1||recurrence:1||reirradiation:1||residual tumor volume:1||response:1||rspiratorygated radiation therapy (RGRT):1||salvage:1||stereotactic ablative body radiotherapy:1||stereotactic body radiation therapy:1||stereotactic body radiotherapy (SBRT):1||stomach cancer:1||supraclavicular lymph node:1||surgery:1||target volume:1||tomotherapy:1||tracking:1||treatment algorithm:1||treatment plan:1||tumor response:1||tumor volume:1||ultracentral (UC) tumor:1||virtual organ delineation:1||고악성도 신경아교종:1||동시항암화학방사선치료:1||부작용:1||예후인자:1||(DRESS)DP:1||코인두암:1||2D and 3D margin:1||3D dose evaluation program:1||4dimesional computed tomography (4DCT):1||ALBI grade:1||Absorbance:1||Adenocarcinoma:1||Adenosquamous carcinoma:1||Adjuvant radiation therapy:1||Adjuvant treatment:1||Automatic registration control:1||BANGkit (TM) gel dosimeter:1||Barcelona Clinic Liver Cancer:1||Biliary invasion:1||Biliary obstruction:1||Body mass index:1||Braindirected treatment:1||Breast cancer recurrence:1||Breast neoplasms:1||Breast reconstruction:1||Breast size:1||Carcinoma:1||Cervical cancer:1||Chemoembolization:1||ChildPugh B:1||Circumferential resection margin:1||Clinical guideline:1||Clinical practice pattern:1||Clinical target volume:1||Clinical trials:1||Colorectal neoplasms:1||Combined modality therapy:1||Concurrent chemoradiation therapy:1||Conebeam computed tomography:1||Cost:1||D2 gastrectomy:1||Deep inspiration breath holding:1||Deformable Registration:1||Diagnosis:1||Dietary habits:1||Diseasefree survival:1||Dose Distribution:1||Dose fractionation:1||Dose linearity:1||Dose volume histogram:1||Doseresponse relationship:1||Dosimetric accuracy:1||Dosimetric index:1||Dosimetrical index:1||EORTCQLQBR23:1||EQ5D:1||Efficacy:1||Elderly:1||Electronic portal image:1||Endometrial carcinoma:1||Endometrial neoplasms:1||Epithelium:1||Esophagitis:1||Extendedfield RT:1||Extrahepatic cholangiocarcinoma:1||Extremity:1||Fraction size:1||Gallbladder cancer:1||Gallbladder neoplasm:1||Gender:1||Glands:1||Gross target volume:1||Guidelines:1||Head and neck cancer:1||Health care:1||

RSS_1.0 RSS_2.0 ATOM_1.0

73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE